Amicus Therapeutics Discloses Strong Preliminary 2025 Financials Amidst BioMarin Acquisition

summarizeSummary

Amicus Therapeutics released preliminary unaudited financial results for 2025, reporting approximately $634 million in total net product revenues and $294 million in cash, cash equivalents, and marketable securities, in connection with its pending acquisition by BioMarin Pharmaceutical Inc.

check_boxKey Events

• Preliminary 2025 Financials Released

  Amicus Therapeutics estimates total net product revenues of approximately $634 million for the year ended December 31, 2025.

• Product Revenue Breakdown

  This includes $522 million from Galafold® and $112 million from Pombiliti® + Opfolda®.

• Strong Cash Position Reported

  The company reported an estimated $294 million in cash, cash equivalents, and marketable securities as of December 31, 2025.

• Context of Pending Acquisition

  These preliminary figures were provided to BioMarin Pharmaceutical Inc. in connection with its proposed acquisition of Amicus, which was announced on January 21, 2026.

auto_awesomeAnalysis

This DEFA14A filing, incorporating an 8-K, provides the first preliminary look at Amicus Therapeutics' full-year 2025 financial performance, which is crucial context for its pending acquisition by BioMarin Pharmaceutical Inc. The reported $634 million in total net product revenues and a strong cash position of $294 million as of year-end 2025 suggest robust operational performance leading into the merger. These figures, though unaudited, offer investors valuable insight into the company's financial health and support the valuation of the $14.50 per share acquisition offer. The disclosure helps shareholders assess the underlying value of Amicus as they consider the proposed transaction.